CS 1103
Alternative Names: CS-1103Latest Information Update: 13 Sep 2024
At a glance
- Originator Clear Scientific
- Developer Clear Scientific; National Institute of Drug Abuse
- Class Drug withdrawal therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Substance-related disorders
Most Recent Events
- 10 Sep 2024 Top line adverse events data from the phase I trial in Substance-related disorders released by Clear Scientific
- 10 Sep 2024 Clear Scientific plans a phase II trial for Substance-related disorders in early 2025
- 06 Jun 2024 Clear Scientific completes a phase-I clinical trials in Substance-related disorders (In volunteers) in USA (IV) (NCT06316973)